|Bid||69.21 x 1400|
|Ask||69.49 x 900|
|Day's range||66.10 - 70.00|
|52-week range||13.53 - 95.21|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2020 - 09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||92.31|
President Trump recently claimed a vaccine will be available within a few weeks, but Dr. Ezekiel Emanuel stressed that Trump’s claims are only wishful thinking.
Moderna has been a much bigger winner than AstraZeneca year to date. Probably the best argument for buying AstraZeneca instead of Moderna is that it's less risky. AstraZeneca, on the other hand, can more readily absorb any setbacks because of its diversified portfolio.
These companies offer compound annual growth rates ranging from a low end of 53% to as much as 140%.